Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite
high rates of response to first-line chemotherapy and radiotherapy, patients with extensive-…

PURPOSE Immune checkpoint inhibitor (ICI) therapy often is suspended because of
immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors for IMDC …

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged
as an important toxicity among patients with cancer. Methods We collected data on 429 …

Recent advances in the treatment of neuroendocrine tumors (NET), including the combination
regimen of capecitabine and temozolomide (CAPTEM), have mostly focused on grade 1 …

Background The neutrophil to lymphocyte ratio (NLR) is known to be prognostic for patients
with advanced cancers treated with immune checkpoint inhibitors (ICI), but has generally …

In this work, we identify co-occurring genomic alterations in KEAP1 , SMARCA4 , and CDKN2A
as independent determinants of poor clinical outcomes with KRAS G12Ci monotherapy …

In an ongoing, open-label, single-arm phase II study ( NCT02927301 ), 181 patients with
untreated, resectable, stage IB–IIIB non-small cell lung cancer received two doses of …

Importance Geriatric (aged ≥80 years) patients are historically underrepresented in cancer
clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in …

PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …

Purpose: We report the intracranial efficacy of selpercatinib, a highly potent and selective
RET inhibitor, approved in the United States for RET fusion-positive non–small cell lung …